Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent GBS Vaccine in Non-Pregnant and Pregnant Women
NCT01193920Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Dec 2011
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of group b streptococcus trivalent vaccine in group B streptococcal infection (6 arms), sponsored by Novartis. Primary endpoints: Percentages of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at Day 61, Antibody Geometric Mean Concentrations in Non-pregnant Women at Day 61 and 2 more. Started Oct 2010; status: completed.
02
Drugs
group b streptococcus trivalent vaccine
03
Conditions
group B streptococcal infection
Beyond the preview
Go deeper on NCT01193920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193920.